Literature DB >> 12786894

E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas.

A S Rocha1, P Soares, E Fonseca, J Cameselle-Teijeiro, M C Oliveira, M Sobrinho-Simões.   

Abstract

AIMS: To investigate the immunohistochemical and molecular genetic features of the cadherins/catenins complex in thyroid carcinoma based on the hypothesis that poorly differentiated carcinoma of the thyroid represents an intermediate step between well-differentiated and undifferentiated carcinomas. METHODS AND
RESULTS: Immunohistochemistry for E-, P- and N-cadherins and alpha-, beta- and gamma-catenins was performed in a series of 17 cases of poorly differentiated carcinoma of the thyroid. All cases showed absence of membranous expression of E-cadherin with no aberrant expression of P- or N-cadherins; regarding catenins there was heterogeneous loss of expression with membranous immunolocalization of the three catenins in most cases. Molecular analysis of the E-cadherin gene and exon 3 of the beta-catenin gene was also performed by polymerase chain reaction/single-strand conformation polymorphism and sequencing. No mutations in either gene were detected in any case.
CONCLUSIONS: In contrast to previous reports, our results suggest that loss of E-cadherin rather than beta-catenin mutation is the crucial event in determining the differentiation 'level' of thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786894     DOI: 10.1046/j.1365-2559.2003.01642.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  28 in total

1.  BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Tália Feijão; Ana Paula Rebocho; Elsa Fonseca; Inês Vieira de Castro; José Cameselle-Teijeiro; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2004-04-17       Impact factor: 4.064

Review 2.  Anaplastic thyroid cancer, tumorigenesis and therapy.

Authors:  J P O'Neill; D Power; C Condron; D Bouchier-Hayes; M Walsh
Journal:  Ir J Med Sci       Date:  2009-08-07       Impact factor: 1.568

3.  Tumor heterogeneity in a follicular carcinoma of thyroid: a study by comparative genomic hybridization.

Authors:  Leonard Da Silva; Daniel James; Peter T Simpson; Daniel Walker; Ana Cristina Vargas; Janani Jayanthan; Sunil R Lakhani; Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

4.  Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.

Authors:  Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Thyroid       Date:  2019-08-16       Impact factor: 6.568

5.  Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours.

Authors:  Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 6.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

7.  Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.

Authors:  Maie A St John; Mariam Dohadwala; Jie Luo; Guanyu Wang; Gina Lee; Hubert Shih; Eileen Heinrich; Kostantyn Krysan; Tonya Walser; Saswati Hazra; Li Zhu; Chi Lai; Elliot Abemayor; Michael Fishbein; David A Elashoff; Sherven Sharma; Steven M Dubinett
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

8.  Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin.

Authors:  Anna Batistatou; Konstantinos Charalabopoulos; Yukihiro Nakanishi; Constantine Vagianos; Setsuo Hirohashi; Niki J Agnantis; Chrissoula D Scopa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

9.  Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.

Authors:  Yoon-La Choi; Mi Kyung Kim; Jin-Won Suh; Joungho Han; Jung Han Kim; Jung Hyun Yang; Seok Jin Nam
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

10.  EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis.

Authors:  Ranju Ralhan; Jun Cao; Terence Lim; Christina Macmillan; Jeremy L Freeman; Paul G Walfish
Journal:  BMC Cancer       Date:  2010-06-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.